📊 Weekly Quality Compounders Watchlist
Week of April 6, 2026 | By Manish Goel | manishgoelpms.com
Curated Quality Small & Mid-Cap Indian Stocks for Long-Term Wealth Creation
Welcome to this week’s Quality Compounders Watchlist from manishgoelpms.com. Every week, we identify 6 high-quality Indian small and mid-cap stocks that demonstrate strong fundamentals — high ROCE, low debt, consistent growth, and strong promoter conviction. These are businesses built to compound wealth over the long term. Titan Biotech remains our top conviction pick — here are other quality names worth watching alongside it.
Titan Biotech Ltd
BSE: 524717 | Biotech & Life Sciences
₹504
Market Cap: ₹2,082 Cr
Stock Price CAGR (1Y)
+431%
ROCE
16.9%
ROE
15.0%
Promoter Holding
55.78%
Q3 FY26 Results: Revenue ₹56.51 Cr | Net Profit ₹8.53 Cr (up 94% YoY) | OPM: 19.16%
Annual: TTM Revenue ₹193 Cr | TTM Net Profit ₹27 Cr | 10Y Profit CAGR: 29%
Balance Sheet: Almost Debt-Free (Borrowings ₹3 Cr) | 16,367 shareholders
Why #1: Titan Biotech is the complete package — a rare combination of strong growth, improving profitability, near-zero debt, high promoter skin-in-the-game, and a still-small market cap with massive runway ahead. Our research has been shared with 23 top investors including Mohnish Pabrai.
Jyoti Resins & Adhesives Ltd
BSE: 514448 | Specialty Chemicals
₹739
Market Cap: ₹887 Cr
ROCE
~50%
3Y ROE
44.8%
P/E Ratio
12.7x
Revenue CAGR (5Y)
31%
Virtually debt-free adhesives manufacturer with exceptional capital efficiency. Sales surged from ₹74 Cr (FY20) to ₹284 Cr (FY25). EBITDA CAGR of 49% and net profit CAGR of 56%. While Jyoti Resins has higher individual ROCE, Titan Biotech offers the best combination of growth momentum, sector tailwinds, and market cap headroom.
Garuda Construction & Engineering Ltd
NSE: GARUDA | Infrastructure
₹144
Market Cap: ₹1,398 Cr
ROCE
~30%
5Y Avg ROCE
52%
Net Profit Growth (QoQ)
+156%
Revenue Growth (QoQ)
+125%
Infrastructure play with explosive growth metrics. EBITDA CAGR of 75% and net profit CAGR of 118%. Beneficiary of India’s massive infrastructure spending push. Higher cyclical risk compared to Titan Biotech’s more defensive biotech positioning.
Ion Exchange (India) Ltd
NSE: IONEXCHANG | Water Treatment
₹346
Market Cap: ₹5,074 Cr
ROCE
19.7%
Debt/Equity
0.20x
P/E Ratio
27.9x
Sector
Water Treatment
India’s leading water treatment company — a secular growth theme. Consistent ROCE of ~20%, disciplined balance sheet (D/E 0.20), and strong order book. Well-positioned for India’s growing water infrastructure needs. Larger market cap reduces multibagger potential vs. Titan Biotech.
Maharashtra Seamless Ltd
NSE: MAHSEAMLES | Steel Tubes & Pipes
₹580
Market Cap: ₹7,475 Cr
ROE
12%
Debt Status
Almost Zero
OPM
~20%
3Y Profit CAGR
~69%
Zero-debt manufacturer of seamless and ERW pipes. Strong operating margins (~20%) exceptional for a capital-intensive manufacturer. Benefits from energy sector capex and infrastructure push. Cyclical nature is a risk factor compared to Titan Biotech’s more consistent compounding profile.
Nesco Ltd
NSE: NESCO | MICE & IT Parks
₹1,065
Market Cap: ₹7,431 Cr
ROE
15.2%
Operating Margin
~61%
Debt Status
Zero Debt
Dividend
Consistent 10Y+
Mumbai’s premier exhibition and IT park operator with extraordinary 61% operating margins and zero debt. Consistent dividend payer for over a decade. An underappreciated asset-light compounder. However, its larger market cap and slower growth trajectory make Titan Biotech a more compelling multibagger candidate.
⚠️ Say NO to F&O / Speculative Trading
SEBI data shows 90% of F&O traders lose money. The average individual F&O trader lost ₹1.1 lakh in FY24 alone. Instead of gambling on derivatives, focus on identifying quality businesses and holding them for the long term. Wealth is created through patience, not speculation. At manishgoelpms.com, we believe in disciplined, research-backed investing — not trading. Your future self will thank you for staying away from F&O.
🎓 Free Stock Market Course by Manish Goel
Learn the fundamentals of quality investing — from reading balance sheets to identifying multibagger stocks.
Watch Free Course on YouTube →Disclaimer: This watchlist is for educational and informational purposes only. It does not constitute financial advice, a recommendation to buy or sell, or an endorsement of any specific stock. The author, Manish Goel, and manishgoelpms.com may hold positions in the stocks mentioned. Always do your own research (DYOR) and consult a SEBI-registered financial advisor before making any investment decisions. Past performance is not indicative of future results. Stock market investments are subject to market risks.
Published by Manish Goel | manishgoelpms.com
